Boston Scientific Offers $25 Bil. To Nab Guidant From J&J
This article was originally published in The Gray Sheet
Executive Summary
Convinced that Johnson & Johnson is undervaluing Guidant, Boston Scientific made an offer of $25 bil. for the cardiovascular device firm on Dec. 5 - approximately $3 bil. more than J&J has agreed to pay
You may also be interested in...
Guidant Shareholders To Vote On J&J Offer; Boston Scientific Still Interested
Guidant's board of directors has formally endorsed Johnson & Johnson's $21.5 bil. takeover bid while simultaneously agreeing to enter into discussions with Boston Scientific on its $25 bil. competing offer
Guidant Shareholders To Vote On J&J Offer; Boston Scientific Still Interested
Guidant's board of directors has formally endorsed Johnson & Johnson's $21.5 bil. takeover bid while simultaneously agreeing to enter into discussions with Boston Scientific on its $25 bil. competing offer
J&J Salvages Deal With Guidant: $4 Bil. Shaved Off Purchase Price
Johnson & Johnson's renegotiated deal to acquire Guidant for $21.5 bil. will make medical devices the firm's largest business segment once the merger closes